K Pharma (4896) Reports Earnings: Operating Loss of 471 Million Yen

K Pharma (4896) has released its latest financial results, reporting an operating loss of 471 million yen, an ordinary loss of 484 million yen, and a net loss of 492 million yen. Earnings per share (EPS) stood at -42.4 yen, reflecting the ongoing upfront investments characteristic of a research-and-development-driven biotech venture.

From a financial and valuation perspective, the company maintains an equity ratio of 30.1% with cash and cash equivalents of 2.36 billion yen. Meanwhile, interest-bearing debt stands at 1.64 billion yen, while operating cash flow and free cash flow registered at -530 million yen and -570 million yen, respectively. With retained earnings at -490 million yen, market participants continue to monitor the balance between capital requirements for pipeline advancement and overall financial stability.